"Is curing patients a sustainable business model?" Goldman Sachs analysts ask
Francis Tseng
Info

One-shot cures for diseases are not great for business-more specifically, they're bad for longterm profits-Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC. The investment banks' report, titled "The Genome Revolution," asks clients the touchy question: "Is curing patients a sustainable business model?"

Connections